Fran Lund, University of Alabama at Birmingham (IMAGE)

University of Alabama at Birmingham

Fran Lund, University of Alabama at Birmingham

Caption

Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today. In animal models at UAB, a single intranasal dose resulted in a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

Credit

UAB

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.